Article

Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men.

Evangelisches Krankenhaus Herne, Wiescherstrasse 24, 44623 Herne, Germany.
European Journal of Endocrinology (impact factor: 3.42). 03/2009; 160(5):815-9. DOI:10.1530/EJE-08-0830 pp.815-9
Source: PubMed

ABSTRACT To compare the effects of two treatment modalities of testosterone on sexual functioning and mood. Design Forty men were randomized to receive either parenteral testosterone enanthate (TE) or long-acting parenteral testosterone undecanoate (TU) over a period of 30 weeks. Thereafter, 20 men who had received TU and 16 men who had received TE continued with TU and completed another 65 weeks to study longer-term effects of TU.
The following variables of sexual functioning were studied: sexual thoughts and fantasy, sexual interest and desire, satisfaction with sex life, number of erections and ejaculations per week, and number of spontaneous morning erections per week. Also variables related to mood were analyzed.
Improvements in these variables were significant and were of a similar magnitude in the group treated with TU and TE for 30 weeks. Improvements were maintained at the same levels over a period of another 65 weeks when all men received TU. Effects on mood were recorded for 30 weeks, but were more difficult to establish in the study population. There were significant differences in baseline values between the two groups and scores showed wide s.d.
Both TE and TU were effective in improving sexual functions in hypogonadal men. An advantage of TU over TE is its lower frequency of administration and its better tolerability and safety profile.

0 0
 · 
0 Bookmarks
 · 
26 Views
  • Source
    Article: Diagnosis and treatment of sexual dysfunctions in late-onset hypogonadism.
    Jin Wook Kim, Du Geon Moon
    [show abstract] [hide abstract]
    ABSTRACT: Testosterone is the principal androgen in the human male. The decline of testosterone with aging was recognized to be associated with a number of symptoms and signs that reduce the quality of life and that may even have severe, debilitating consequences. Clinically, late-onset hypogonadism (LOH) is diagnosed by use of biochemical and clinical measures. Despite published guidelines and recommendations, however, uncertainty surrounds the profile of clinical symptoms as well as the biochemical threshold of diagnosis. Clinicians should be aware of these shortcomings while adhering to the guidelines. Current treatment methods are centered on restoring testosterone to mid to lower levels of young men with natural testosterone replacements. Although recent studies have highlighted possible additional benefits involving improvement of systemic disorders, the goal of treatment is to improve sexual function, while observing for adverse effects in the prostate. Overall, the problem of LOH in debilitating the quality of life and well-being is real, and by following proper guidelines with attentiveness to the results of treatment trials, testosterone replacement therapy presents a safe and effective treatment option.
    Korean journal of urology 11/2011; 52(11):725-35.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

baseline values
 
following variables
 
hypogonadal men
 
Improvements
 
long-acting parenteral testosterone undecanoate
 
lower frequency
 
parenteral testosterone enanthate
 
safety profile
 
sex life
 
sexual interest
 
sexual thoughts
 
similar magnitude
 
spontaneous morning erections
 
study longer-term effects
 
study population
 
TE
 
testosterone
 
treatment modalities
 
two groups
 
wide s.d